EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Sharad Ghamande, Jung-Yun Lee, Susana Banerjee, Fernando Cotait Maluf, Domenica Lorusso, Kan Yonemori, Els Van Nieuwenhuysen und 20 weitere

New England Journal of Medicine · 04.07.2024 · 391 (1) · 44-55

DOI: 10.1056/nejmoa2313811 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 04.07.2024. Verfasst von Ignace Vergote und 31 weiteren Autor:innen. Beteiligte Einrichtung: From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local, Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 220-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Genmab A/S, Seagen Inc., which was acquired by Pfizer Inc. in Dec 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. METHODS: We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio, to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every 3 weeks) or the investigator's choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was overall survival. RESULTS: A total of 502 patients underwent randomization (253 were assigned to the tisotumab vedotin group and 249 to the chemotherapy group); the groups were similar with respect to demographic and disease characteristics. The median overall survival was significantly longer in the tisotumab vedotin group than in the chemotherapy group (11.5 months [95% confidence interval {CI}, 9.8 to 14.9] vs. 9.5 months [95% CI, 7.9 to 10.7]), results that represented a 30% lower risk of death with tisotumab vedotin than with chemotherapy (hazard ratio, 0.70; 95% CI, 0.54 to 0.89; two-sided P = 0.004). The median progression-free survival was 4.2 months (95% CI, 4.0 to 4.4) with tisotumab vedotin and 2.9 months (95% CI, 2.6 to 3.1) with chemotherapy (hazard ratio, 0.67; 95% CI, 0.54 to 0.82; two-sided P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalUterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedOligopeptidesAdultAgedAged, 80 and overFemaleHumansMiddle AgedKaplan-Meier EstimateProgression-Free SurvivalSurvival Analysis

Substanzen

tisotumab vedotinAntibodies, Monoclonal, HumanizedOligopeptides

Autor:innen und Institutionen

  • From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E.V.N.), and Centre Hospitalier Universitaire de Liège, Liege (C.G.) -…

Förderung

  • Genmab A/S
  • Seagen Inc., which was acquired by Pfizer Inc. in Dec 2023

Zitieren

APA

Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., Lee, J. Y., Banerjee, S., Maluf, F. C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso, L., Woelber, L., Westermann, A., Covens, A., Hasegawa, K., Kim, B. G., Raimondo, M., …, & innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators (2024). Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine, 391(1), 44-55. https://doi.org/10.1056/nejmoa2313811

Vancouver

Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine. 2024;391(1):44-55. doi:10.1056/nejmoa2313811

BibTeX
@article{Vergote2024,
  author = {Vergote, Ignace and González-Martín, Antonio and Fujiwara, Keiichi and Kalbacher, Elsa and Bagaméri, Andrea and Ghamande, Sharad and Lee, Jung-Yun and Banerjee, Susana and Maluf, Fernando Cotait and Lorusso, Domenica and Yonemori, Kan and Van Nieuwenhuysen, Els and Manso, Luis and Woelber, Linn and Westermann, Anneke and Covens, Allan and Hasegawa, Kosei and Kim, Byoung-Gie and Raimondo, Miriam and Bjurberg, Maria and Cruz, Felipe Melo and Angelergues, Antoine and Cibula, David and Barraclough, Lisa and Oaknin, Ana and Gennigens, Christine and Nicacio, Leo and Teng, Melinda Siew Leng and Whalley, Elizabeth and Soumaoro, Ibrahima and Slomovitz, Brian M and innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators, innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators},
  title = {Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {1},
  pages = {44--55},
  doi = {10.1056/nejmoa2313811}
}
Kostenlos starten →